SEC Tracker
Get the app

Aspen Neuroscience ASPE

ARCH Venture Fund X, L.P. (10% owner) bought 1,333,333 ASPE at $15.00, worth $20M

Form
4
Filed
Importance
Major
  1. Arch Venture Fund X, L.P. acquired 66,666 shares at $15
  2. Multiple transactions show cumulative ownership of 1,393,848 shares
  3. Options and similar rights include 187,182 Series Seed Convertible Preferred Stock

Written from the Form 4 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Aspen Neuroscience files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing identifies ARCH Venture Fund X, L.P. as the reporting person, with an address in Chicago, Illinois.
  2. The issuer named is Aspen Neuroscience, Inc., with the ticker symbol ASPE.
  3. The form indicates a transaction involving common stock on November 2, 2026.
  4. The filing includes a transaction code P, indicating a purchase.
  5. The amount of securities acquired is listed as 66 shares.
  6. The ownership is direct, and no indirect ownership is noted in the form.

6 of 7 claims matched the filing text.

Not found in the filing text

  • The form was submitted to the SEC and is accessible under the accession number 0001193125-26-444147.

From the filing

Filing text

SEC Form 4

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP4

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

See

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1.1 1Name and Address of Reporting Person * ARCH Venture Fund X, L.P.1

(Last) (First) (Middle)

8755 W. HIGGINS ROAD, SUITE 1025

(Street) CHICAGO1

ILLINOIS1

60631

(City) (State) (Zip)

UNITED STATES

(Country) 2.2 2Issuer Name and Ticker or Trading Symbol2

Aspen Neuroscience, Inc.2

[ ASPE ]2

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable) Director X 10% Owner

Officer (give title below) Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction

(Month/Day/Year)

11/02/2026 65. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

X Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed

(Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr.

3)

2. Transaction Date

(Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr.4

8)4

4. Securities Acquired (A) or Disposed Of (D)5 (Instr.

3, 4 and 5)

5.

Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.

3 and 4)

6. Ownership Form: Direct (D) or Indirect (I)6 (Instr.

4)

7. Nature of Indirect Beneficial Ownership (Instr.

4)

Code V Amount (A) or (D) Price

Common Stock 11/02/20263 P 66

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX